Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus MICRONASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus MICRONASE.
CHLORPROPAMIDE vs MICRONASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, leading to membrane depolarization, calcium influx, and exocytosis of insulin.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
Initial dose: 2.5-5 mg orally once daily with breakfast. Maintenance: 1.25-20 mg daily in single or divided doses. Maximum: 20 mg/day.
None Documented
None Documented
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Terminal elimination half-life: 10 hours (range 7-20); clinical context: duration of action may be prolonged in renal impairment.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Renal: approximately 50% as metabolites and unchanged drug; biliary/fecal: approximately 50% as metabolites.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."